Abstract
Hypoxia in tumor cells is characterized by a lack of oxygen resulting from reduced blood supply to the surrounding tissue, and is a common characteristic of solid tumors as a consequence of rapid cell growth. Hypoxia in tumors is a predictor of both resistance to chemotherapy and of a metastatic/aggressive form of cancer, and as a result, development of cancer therapies which target hypoxia is of vital importance. One such targeting strategy is the development of hypoxia-activated prodrugs (HAP) which can preferentially release chemotherapeutic agents within hypoxic tumor regions. This targeting strategy is accomplished by attaching a hypoxia activated trigger to a chemotherapeutic agent and under oxygen-poor conditions, the agent (effector) is released into the tumor, while remaining intact in normal tissue, and leaving non-hypoxic cells undamaged. Overall, this strategy can achieve an increased therapeutic benefit over conventional small molecule chemotherapeutic treatments by concentrating the drugs within hypoxic tumor environments, while simultaneously reducing the side-effects and toxicity issues that surround the systemic distribution of traditional drugs on normoxic cells. In this review, we will describe the factors that should be considered when designing an effective HAP, such as the mechanism of prodrug action, the elements that influence the rational design of HAP (i.e. reduction potential), and the activating enzymes of HAP. As part of this description, we will utilize select examples from the literature to reinforce these factors, and make a case for the intelligent design of new HAPs, leading to the development of novel hypoxia targeting chemotherapeutic agents.
Keywords: Hypoxia, prodrug, targeted chemotherapy, bioreductive, antineoplastic agents.
Current Medicinal Chemistry
Title:Hypoxia Activated Prodrugs: Factors Influencing Design and Development
Volume: 22 Issue: 37
Author(s): Dinghua Liang, Graham H. Miller and Geoffrey K. Tranmer
Affiliation:
Keywords: Hypoxia, prodrug, targeted chemotherapy, bioreductive, antineoplastic agents.
Abstract: Hypoxia in tumor cells is characterized by a lack of oxygen resulting from reduced blood supply to the surrounding tissue, and is a common characteristic of solid tumors as a consequence of rapid cell growth. Hypoxia in tumors is a predictor of both resistance to chemotherapy and of a metastatic/aggressive form of cancer, and as a result, development of cancer therapies which target hypoxia is of vital importance. One such targeting strategy is the development of hypoxia-activated prodrugs (HAP) which can preferentially release chemotherapeutic agents within hypoxic tumor regions. This targeting strategy is accomplished by attaching a hypoxia activated trigger to a chemotherapeutic agent and under oxygen-poor conditions, the agent (effector) is released into the tumor, while remaining intact in normal tissue, and leaving non-hypoxic cells undamaged. Overall, this strategy can achieve an increased therapeutic benefit over conventional small molecule chemotherapeutic treatments by concentrating the drugs within hypoxic tumor environments, while simultaneously reducing the side-effects and toxicity issues that surround the systemic distribution of traditional drugs on normoxic cells. In this review, we will describe the factors that should be considered when designing an effective HAP, such as the mechanism of prodrug action, the elements that influence the rational design of HAP (i.e. reduction potential), and the activating enzymes of HAP. As part of this description, we will utilize select examples from the literature to reinforce these factors, and make a case for the intelligent design of new HAPs, leading to the development of novel hypoxia targeting chemotherapeutic agents.
Export Options
About this article
Cite this article as:
Liang Dinghua, Miller H. Graham and Tranmer K. Geoffrey, Hypoxia Activated Prodrugs: Factors Influencing Design and Development, Current Medicinal Chemistry 2015; 22 (37) . https://dx.doi.org/10.2174/0929867322666151021111016
DOI https://dx.doi.org/10.2174/0929867322666151021111016 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
BRCA1 and BRCA2 Molecular Testing in Women with Different Risk of Hereditary Breast Cancer: ost/Effectiveness and Psychological Implications
Current Women`s Health Reviews MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Current Nanoscience Ras-Induced Senescence and its Physiological Relevance in Cancer
Current Cancer Drug Targets Isolation, Characterization and Preliminary Cytotoxic and Antifungal Evaluations of Novel Lancifoliate Isolated from Methanol Extract of <i>Conocarpus lancifolius</i>
Anti-Cancer Agents in Medicinal Chemistry Classification of Malignant and Benign Micro Calcifications from Mammogram Using Optimized Cascading Classifier
Current Signal Transduction Therapy Seeds of Peganum Harmala L. Chemical Analysis, Antimalarial and Antioxidant Activities, and Cytotoxicity Against Human Breast Cancer Cells
Medicinal Chemistry Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
Current Topics in Medicinal Chemistry Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Innate Immunity and Vaccines
Current Topics in Medicinal Chemistry The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Meet Our Editorial Board Member
Letters in Drug Design & Discovery Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Acknowledgements to Reviewers:
Current Cancer Therapy Reviews Photoprotective Carotenoids Lutein and Zeaxanthin: Their Role in AMD
Current Nutrition & Food Science Editorial [Hot Topic: Molecular Imaging in Current Pharmaceuticals (Guest Editor: Ramasamy Paulmurugan)]
Current Pharmaceutical Biotechnology Synthesis of Coumarin linked Naphthalimide Conjugates as Potential Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews